

NEW DEVELOPMENTS IN MULTIPLE MYELOMA

AGENDA

FRIDAY, MAY 15, 2009

Registration opens at 10:00 am. Lunch buffet available from 12:00

13.00 – 13.05 Welcome & opening words

13.05 – 13.30 Keynote lecture

J. San Miguel, J.L. Harousseau

R. Kyle

SESSION I: Biology and prognostic Indicators

13.30 – 13.50 Phenotype of the myeloma cell. Clinical implications

13.50 – 14.10 Signal transduction and apoptosis

14.10 – 14.30 The use of cytogenetics for defining prognosis and tailoring treatment

Chair: *J. San Miguel*

J. San Miguel

C. Pellat

J. Drach

SESSION II: The role of novel agents in front-line therapy in elderly patients

14.30 – 14.50 Thalidomide

14.50 – 15.10 Bortezomib

15.10 – 15.30 Lenalidomide

15.30 – 15.50 Is there a role for autologous stem-cell transplantation?

15.50 – 16.10 Panel discussion: Optimal treatment of elderly patients: questions to be addressed in randomised trials

16.10 – 16.30 *Coffee break*

Chair: *M. Boccardo*

C. Hulin

M.V. Mateos

A. Palumbo

H. Einsele

*M. Boccardo, M.V. Mateos,
A. Palumbo, H. Einsele*

SESSION III: Fighting the disease: maximizing benefits while minimizing side-effects

16.30 – 16.50 Renal failure

16.50 – 17.10 The bone and the expert: what is the 2009 consensus?

17.10 – 17.30 Side effects of new therapies: how to prevent and handle

17.30 *Closure of the day*

20.00 *Course dinner (pre-registration required)*

Chair: *H. Ludwig*

H. Ludwig

E. Terpos

M. Boccardo

SATURDAY, MAY 16, 2009

SESSION IV: The role of novel agents in the context of transplantation

Chair: *JL Harousseau*

- 08.30 – 08.50 Induction treatment prior to autologous stem cell transplantation *M. Cavo*
- 08.50 – 09.10 Novel agents given before and after autologous stem cell transplantation *M. Attal*
- 09.10 – 09.30 The role of novel agents in allogeneic stem-cell transplantation *N. Kröger*
- 09.30 – 09.50 Panel discussion: Optimal treatment of younger patients: questions to be addressed in randomized trials *J.L. Harousseau, M. Cavo, M Attal, P. Sonneveld, N. Kröger*
- 09.50 – 10.10 *Coffee break*

SESSION V: Treatment of relapsed disease

Chair: *P. Sonneveld*

- 10.10 – 10.30 How to design and interpret clinical trials in relapsed Multiple Myeloma: definition of the population and of the objectives *M. Delforge*
- 10.30 – 10.50 Novel agents in evaluation *E. Ocio*
- 10.50 – 11.10 Panel discussion: Current strategies in relapsed Multiple Myeloma *All speakers*

SESSION VI: Current algorithms and future perspectives

Chair: *J. San Miguel*

- 11.10 – 11.30 The use of new genetic tools for prognostication in Multiple Myeloma - introduction on risk-adapted strategy *H. Avet-Loiseau*
- 11.30 – 11.50 Should complete remission be the primary objective of therapy? *J.L. Harousseau*
- 11.50 – 12.10 The role of continuous therapy: searching for the cure or changing Multiple Myeloma into a chronic disease. *P. Sonneveld*
- 12.10 – 12.20 *Learning assessments: Attendees to fill in their evaluation forms and answer 15 questions based on the course. Certificates will be given ONLY afterwards*
- 12.20 - 14.00 *Lunch-buffet and certificate delivery*